Deep Intelligence Across Industries

Company Headquarters: Michigan, US Founded: 1941 Workforce: ~51,000 Company Working: Stryker is engaged in developing, manufacturing, and marketing specialty surgical and medical products. Its products include implants, biologics, surgical, neurologic, ear, throat, interventional pain equipment, endoscopic, surgical navigation, communications, and digital imaging systems. The company also offers products for patient handling and emergency medical equipment. It operates through three major segments: medical & surgical equipment (MedSurg), orthopedics, and neurotechnology & spine. Stryker has been focused on providing automation solutions in its product portfolio. It has a presence in over 75 countries across the globe.

Company Headquarters: Italy Founded: 1997 Workforce: ~6000 Company Working: Versalis SpA, owned and controlled by Eni SpA, produces petrochemical products such as basic chemicals, polyethylene, elastomers, and styrenes. Versalis is among the leading manufacturers of polyethylene and polystyrene, used mainly for flexible packaging. It operates through the intermediate and polymer segments and offers polyethylene products such as low- and high-density polyethylene, very low- and linear-density polyethylene, and pharmacopeia-compliant polyethylene. The company serves various end-use industries such as automotive, packaging, medical, construction, and packaging.

Company Headquarters: Switzerland Founded: 1998 Workforce: ~7000 Company Working: INEOS, is renowned as a global manufacturer of petrochemicals, specialty chemicals, and oil products. The company has 32 manufacturing sites in six countries globally. The company operates through olefins & polymers Europe, olefins & polymers North America, and chemical intermediates. It produces polyolefins ranging from HDPE, LLDPE, LDPE, and m LLDPE to PP products. The company serves numerous industries such as packaging, construction, automotive, durables, agrochemicals and pharmaceuticals.

Company Headquarters: Goose Creek, South Carolina, US Founded: 2014 Workforce: ~1,000 Company Working: TRU Simulation + Training Inc. is a manufacturer of flight simulators and training solutions for civil and military markets. The company operates as a subsidiary of Textron Inc., which designs and develops aircraft, helicopters, golf cars, off-road utility vehicles, spare parts, and other products worldwide. Textron operates through five business segments—bell helicopter, Textron aviation, Textron systems, industrial, and finance. Through its industrial business segment, the company offers catalytic reduction systems, plastic bottles and containers, golf cars, off-road utility and light transportation vehicles, recreational and all-terrain vehicles. Through its Textron aviation segment, it offers business jets, turboprop and piston engine aircraft, and military trainer and defense aircraft. The Textron Systems segment covers unmanned systems, marine and land systems, electronic systems, advanced information solutions, geospatial solutions, weapon and sensor systems, piston engines, simulation, training, and other defense and aviation mission support products and services. Textron has 63 manufacturing facilities located in the US and 52 plants outside the US. It has approximately 35 subsidiaries, which include companies such as Lycoming Engines, AAI Corporation, Aerosonde Ltd, and HR Textron Inc. In the helicopter simulator market, the company faces competition by the regional company CAE Incorporated.

Borealis is Europe's technology-led polyolefins producer and, since 31 March 2026, the European pillar of Borouge International, the world's fourth-largest polyolefins group by nameplate capacity. Its franchise rests on three things: proprietary process and catalyst technology (Borstar, Borstar Nextension, Borlink); a specialty-weighted portfolio serving wire and cable, pipe, automotive, healthcare and advanced packaging; and an early position in mechanical and chemical recycling. It sold 4.07 million tonnes of polyolefins in 2025 from integrated sites in Austria, Belgium, Finland, Germany and Sweden. It is, however, a high-cost European producer in an oversupplied global market: operating profit fell to EUR 50 million in 2025 on EUR 7.70 billion of sales, and until 2025 most of its net profit came from its Borouge stake rather than its own operations. Inside BGI, Borealis contributes technology, application know-how and European customers, while low-cost feedstock sits in Abu Dhabi and North America. --- **The company's own description.** In AR2025 Borealis presents itself as a global leader in chemical and polyolefin solutions with two product groups that have a market presence, Polyolefins (polyethylene and polypropylene) and Base Chemicals (ethylene, propylene and other base chemicals), and as an innovative leader in polyolefin recycling in Europe. Its stated corporate purpose, shared with OMV, is "Reinventing Essentials for Sustainable Living". **Independent characterization.** Borealis is a European olefins and polyolefins manufacturer with partial backward integration into monomers. It runs steam crackers at Porvoo and Stenungsund and a propane dehydrogenation unit at Kallo, with a second world-scale unit due to start in the second half of 2026. Sites at Schwechat and Burghausen take olefins from adjacent OMV refineries. It converts these monomers into polyethylene and polypropylene, a substantial share of which goes into compounded and specialty grades. **Revenue model.** Revenue is almost entirely product sales, priced off monthly European monomer and polymer contract benchmarks; inter-segment transfers are based mainly on monthly market prices (HY2025). Technology licensing and catalyst supply (Borstar) exist but are not disclosed as a separate revenue line. There is no subscription or service revenue of note. A minor "Other" line was about 3% of 2024 net sales (Debt Investor Presentation 2025), and AR2025 discloses EUR 270 million of non-core fossil-related revenue in 2025, mainly temporary feedstock trading linked to the delayed Kallo start-up and cracker co-products. **Value chain position.** Upstream inputs are light naphtha, butane, propane, ethane and refinery streams, plus renewable and waste-based feedstock and purchased energy. Downstream customers are converters and compounders, with brand owners and retailers further along the chain (AR2025, ESRS 2 SBM-1). **Customer and end-market clusters (AR2025):** - Healthcare: pharmaceutical packaging, medical and diagnostic devices. - Consumer products: appliances, fibres, flexible and rigid packaging, foam. - Mobility: vehicle interiors and exteriors, battery applications, front-end carriers. - Energy: cables, energy storage, solar. - Infrastructure: pipes and fittings. - Solutions for polymers: modifiers, masterbatch and compound carriers, foam solutions. **Earnings structure.** Three profit pools mattered historically: European integrated polyolefins, base chemicals, and equity-accounted joint ventures (Borouge, positive; Baystar, negative). After the March 2025 agreement, Borouge was reclassified as a discontinued operation held for sale, and in 2026 the Borouge shares moved to BGI. The standalone Borealis that remains is therefore a European operating business plus the 50% Baystar interest, with a much smaller equity base.

Company Headquarters: Montréal, Québec, Canada Founded: 1947 Workforce: ~8000 Company Working: CAE Inc. is a global leader in the delivery of training and training devices to the defense & security, civil aviation, and healthcare industries. The company is involved in the design and integration of its most comprehensive training solutions for the defense & security applications. It has a global presence with 160 sites and training locations across 35 countries. The company has joint venture operations with aviation training service providers such as Description Deutsche Lufthansa AG, Leonardo S.p.a., and InterGlobe Enterprises Pvt Ltd with the world's largest base of flight simulators. It trains more than 120,000 civil and defense crew members, as well as thousands of healthcare professionals on an annual basis. The company specializes in providing simulation and training; flight simulators and healthcare simulators; various services to manage and optimize mining operations and training centers; software designing; and software engineering.

UPL Limited is India's largest agrochemical company by revenue and one of the world's five largest crop-protection players, with FY26 consolidated revenue of ₹51,839 crore (≈US$5.9bn) and a presence in more than 140 countries. Its distinctive model blends a low-cost, backward-integrated Indian manufacturing base for off-patent active ingredients with a global formulation, registration and distribution network built largely through the 2019 acquisition of Arysta LifeScience. The group is organised into four "pure-play" platforms: UPL Corporation (international crop protection), UPL SAS (India crop protection), Advanta (global hybrid seeds and post-harvest) and SUPERFORM (active ingredients and specialty chemicals). Over 2024–2026 UPL has executed a deleveraging programme — rights issue, Advanta minority sales, US$850m gross debt reduction in FY26 — and launched a simplification restructuring creating UPL Global, alongside a pending Advanta IPO. The equity, however, trades near multi-year lows on leadership turnover, holdco discount and execution concerns. --- ### What UPL does UPL manufactures, formulates, registers and sells crop-protection products (herbicides, insecticides, fungicides, plant-growth regulators, seed treatments), biosolutions branded under "Natural Plant Protection" (NPP), hybrid seeds (field corn, sunflower, sorghum, canola, rice, vegetables), post-harvest solutions (fruit coatings, fungicides and storage treatments under the Decco brand), and industrial/specialty chemicals including active ingredients sold to third parties. The company's own description (Q1 FY27 press release, 3 Aug 2026) presents UPL as a global provider of sustainable agricultural products and solutions spanning the whole agrifood value chain, organised through four pure-play platforms: UPL Corporation Ltd, UPL Sustainable Agri Solutions Ltd (UPL SAS), Advanta Enterprises Ltd and SUPERFORM Chemistries Ltd (formerly UPL Speciality Chemicals Ltd). ### Business model UPL's economic engine is the post-patent (generic) agrochemical model, enhanced with differentiation: 1. **Backward integration in India**: Gujarat-based plants manufacture technical-grade active ingredients (AIs) and intermediates at low cost; SUPERFORM supplies both UPL's own crop-protection platforms and third parties. 2. **Global registration moat**: Thousands of product registrations across Latin America, North America, Europe and Asia — inherited and expanded via Arysta — create barriers for pure generic exporters. In FY26 UPL Corp launched 300+ new products generating US$160m+ revenue from new launches (FY26 earnings presentation). 3. **Differentiated and sustainable portfolio**: Combination products, proprietary mixtures, biosolutions (NPP) and "ProNutiva" seed-to-harvest programmes. Management expects ≈US$700m of FY27 revenue from the sustainable solutions portfolio (Q1 FY27 call). The FY25 sustainability report states 38% of revenue came from differentiated and sustainable solutions. 4. **Seeds**: Advanta breeds and sells locally adapted hybrids with 900+ varieties across 21 breeding crops, distributed in 74 countries (Advanta DRHP, as of 30 Sep 2025). 5. **Distribution and channel credit**: Sales go through distributors, retailers and co-operatives; extended credit terms (notably in Brazil) make working capital a central management variable. ### Revenue model mix | Revenue type | Description | Approx. share of FY26 platform revenue | |---|---|---| | Crop protection products (UPL Corp + UPL SAS) | Branded/generic formulations, biosolutions | ~71% | | Seeds and post-harvest (Advanta) | Hybrid seeds, Decco post-harvest | ~12% | | Active ingredients & specialty chemicals (SUPERFORM) | AIs (partly captive), super-specialty chemicals | ~18% (incl. inter-segment) | | Services / licensing / digital | Nurture.farm digital services (transferred to Nurture Agtech), minor licensing | Not separately disclosed; immaterial | UPL is overwhelmingly a product business. There is no material subscription or licensing revenue disclosed. Approximate FY26 platform mix (gross, before inter-segment eliminations; FY26 earnings release): Note: Platform revenues sum to more than consolidated revenue because SUPERFORM sells AIs to the crop-protection platforms (eliminated on consolidation). Management stated non-agchem revenue share is roughly 27% (Q3 FY26 press release). ### Value chain position UPL spans: intermediates → technical AI manufacture (SUPERFORM) → formulation (India and international plants) → registration and regulatory dossiers → branded distribution to growers; plus germplasm/breeding → seed production → seed sales (Advanta); and post-harvest treatments for fruit and vegetable packers (Decco). ### Customer types and end-markets | Customer type | Platform | End-markets | |---|---|---| | Distributors, retailers, co-operatives | UPL Corp, UPL SAS | Row crops (soy, corn, cotton, sugarcane, rice, wheat), fruits & vegetables, specialty crops | | Large growers / farm enterprises | UPL Corp (Brazil, US) | Soybean, corn, sugarcane, cotton | | Seed dealers, growers | Advanta | Tropical field corn (India, Thailand, Indonesia, LatAm), sunflower and sorghum (Argentina), canola (Australia), vegetables | | Packhouses, exporters | Advanta (Decco) | Citrus, apples, pears, bananas, stone fruit | | Agrochemical and industrial companies | SUPERFORM | AI supply, specialty chemicals, industrial intermediates | ### Independent characterisation UPL is best understood as a leveraged, emerging-market-origin consolidator of the global off-patent crop-protection market that is in transition toward a holding-company structure with separately listed operating assets. Its competitive edge is cost and registration breadth rather than discovery chemistry; its key weaknesses are cyclicality (the 2023–24 channel destocking cut revenue 20% and produced a loss), high financial leverage relative to rated peers (sub-investment-grade at the UPL Corp level), and governance perceptions tied to complex inter-company structures. The 2026 restructuring (UPL Global) and the Advanta IPO are explicit attempts to remedy the conglomerate discount — DAM Capital estimates the holdco discount at ~61% (Aug 2026).

Company Headquarters: Yokohama, Japan Founded: 1942 Workforce: ~2,364 Company Working: Sakata Seed Corporation (Sakata) produces and sells vegetable seeds, flower seeds, grass seeds, vegetable seedlings, flower seedlings, bulbs, and agricultural/gardening materials in Japan and other parts of the globe. It is also engaged in the publication of gardening literature; R&D and contract production of seeds; and the design, management, and contract of various constructions, such as landscaping, greenhouse, and agricultural facilities. It offers okra seeds through its subsidiary Sakata Seed America. The company was formerly known as T. Sakata & Company and changed its name in January 1986.

Company Headquarters: Massachusetts, US Founded: 2015 Workforce: ~370+ Company Working: Mustang Bio is a subsidiary of Fortress Biotech, Inc. It is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient’s immune system to eliminate cancer cells. Mustang Bio aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. Mustang has partnered with the City of Hope National Medical Center (COH) and Fred Hutchinson Cancer Research Center in the development of proprietary CAR T therapies for many cancers. Mustang Bio’s lead programs are in Phase 1 clinical trials at COH: MB-101 for the treatment of brain cancer and MB-102 as a therapeutic agent in acute myeloid leukemia

Company Headquarters: New Jersey, US Founded: 2014 Workforce: ~500 Company Working: Legend Biotech is a multinational biopharmaceutical company. The company has three core cell therapy platforms—CAR-T) T-cell receptor T-cell therapy (TCR-T), and allogeneic cell therapy. The company has been developing a strong pipeline of CAR-T products to treat solid and liquid tumors. Legend Biotech is utilizing the extensive cell therapy experience of its leaders and R & D staff, global clinical partners, and expanding research facilities. It is doing so to utilize the potential of cell therapy to treat diseases that are thought to be incurable, such as hematologic malignancies, solid tumors, infectious diseases, and autoimmune diseases

Company Headquarters: Washington, US Founded: 2013 Workforce: ~500 (2016) Company Working: Juno Therapeutics is a part of Celgene Corporation. It is a biopharmaceutical company formed through the collaboration of Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company is into the development of cell-based cancer immunotherapies based on chimeric antigen receptor (CAR) and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno Therapeutics is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as multiple solid tumors and multiple myeloma. The company has its offices in the US and Germany. The company has its manufacturing plant in Washington, US.

Company Headquarters: France, Paris Founded: 1999 Workforce: ~161 Company Working: Cellectis is a clinical stage biotechnological company involved in the development of immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company operates through two segments—Therapeutics and Plants. Cellectis is currently developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL), UCART22 to treat ALL and non-Hodgkin lymphoma (NHL), ALLO-501 for treating relapsed/refractory NHL, and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm, among others

Lonza is the world's largest and longest-established pure-play contract development and manufacturing organization (CDMO). It sells development, manufacturing and technology services to pharmaceutical and biotechnology companies across the main modalities: - mammalian and microbial biologics; - small-molecule APIs and drug products; - antibody-drug conjugates (ADCs) and bioconjugates; - cell and gene therapies; - mRNA. Following the March 2026 agreement to sell Capsules & Health Ingredients (CHI) to Lone Star Funds, Lonza is completing a two-year transformation into a focused CDMO. It now operates three business platforms: Integrated Biologics, Advanced Synthesis and Specialized Modalities. Its differentiation rests on four things: - scale, including Visp, Vacaville (the largest US biologics CDMO site) and Portsmouth; - an integrated drug-substance-to-drug-product offering; - a proprietary toolbox: GS Xceed® expression, Ibex®, Synaffix® ADC linkers and the Nona TfR1 BBB technology; - a quality track record across 125+ years of chemical and biological manufacturing. FY2025 continuing sales were CHF 6.5bn at a 31.6% CORE EBITDA margin. Management guides FY2026 to 11–12% CER growth and a 33–34% margin. --- **Company's own description.** In its 2026 releases Lonza calls itself the world's leading CDMO "dedicated to serving the healthcare industry." It describes a team of around 20,000 people working with pharma and biotech customers to turn breakthrough innovations into viable therapies, using science, smart technology and lean manufacturing (H1 2026 release boilerplate). The FY2025 FYR and AR2025 present the business as three complementary, integrated CDMO Business Platforms "powered by the Lonza Engine®." The Lonza Engine is the company's term for its combined strengths in science, smart technology and lean manufacturing for complex and emerging modalities (6 Mar 2026 release). **What Lonza does.** Lonza takes a customer's molecule, from DNA sequence or chemical route, and develops and manufactures it. Work runs from pre-clinical development through clinical supply to commercial launch and lifecycle manufacturing. Revenue comes from four sources: **Development services:** Cell-line development, process and analytical development, formulation and regulatory CMC. Typically billed fee-for-service or per milestone. **Clinical and commercial manufacturing:** Drug substance and drug product. Usually batch-based or capacity-reservation contracts, often with take-or-pay or minimum-volume features. Large commercial deals are frequently multi-year and sometimes involve customer co-funding of dedicated capacity, as in the Ibex model and the 2026 Stein ADC line backed by a long-term customer commitment. **Technology licensing:** GS Xceed® expression system licences, Synaffix ADC technology licences with upfront/milestone/royalty structures, bYlok® and the Nona TfR1 BBB platform. **Products (Bioscience):** Cell-culture media, primary cells, transfection systems (Nucleofector™), endotoxin and microbial testing. Sold as consumables and instruments. **Revenue-model mix.** Lonza does not publish an exact split between product, service, subscription and licensing revenue. The analyst estimate is that more than 90% of continuing revenue is service-based CDMO revenue (development plus manufacturing). The rest is Bioscience products, reported within Specialized Modalities, and technology licensing. There is no subscription revenue. Licensing is strategically important as a customer-acquisition funnel but financially small; its amount is not separately disclosed. **Value-chain position.** Lonza sits between drug innovators (big pharma, mid-cap and small biotech) and patients. It is an outsourced manufacturer that carries large fixed-asset intensity: - PP&E of CHF 8.3bn at FY2025 (S&P/StockAnalysis); - CapEx of CHF 1.3bn in FY2025, 19.6% of sales (FY2025 FYR). Its upstream suppliers are equipment, single-use consumable, raw-material and media vendors. Downstream, its customers own the regulatory licences and commercialize the drugs. **Customer types:** 1. Large pharmaceutical companies outsourcing commercial capacity. Examples are the strategic multi-site US biopharma collaboration expanded on 1 Jul 2026 and the Vacaville commercial contracts. 2. Mid-size and emerging biotech needing integrated DNA-to-IND and clinical supply. Example: the ImmuneOncia late-stage mAb deal, March 2026. 3. Academic and research customers (Bioscience). 4. Cell and gene therapy developers (autologous and allogeneic). **End-markets.** The main end-markets are: - biologic therapeutics (mAbs, bispecifics, fusion proteins); - ADCs and bioconjugates in oncology; - small-molecule APIs including highly potent APIs (HPAPI); - cell and gene therapy; - microbial-derived proteins, peptides and enzymes; - mRNA/LNP; - research tools. **Analyst characterization.** Lonza is a capital-heavy, scale-advantaged infrastructure provider to biopharma. Its economics depend on asset utilization: - New plants dilute margins during ramp-up. This was visible in FY2023, when the CORE EBITDA margin fell to 29.8%, and in early Vacaville. - Mature, full assets earn returns well above group average. Advanced Synthesis reached a 48.1% CORE EBITDA margin in H1 2026. The CHI exit removes a lower-growth consumer-health and capsule business that lacked CDMO synergy. It turns Lonza into a purer "picks-and-shovels" exposure to biologic and complex-modality pipelines. The key debates are: - the pace of capacity absorption at Vacaville and Visp large-scale; - competitive intensity from Asian CDMOs and big-pharma insourcing; - capital intensity versus free-cash-flow conversion.

Company Headquarters: US Founded: 1991 Workforce: 13,755+ Company Working: Gentherm is a global technology and industry leader in designing, developing, and manufacturing innovative thermal management technologies. Its products provide solutions for automotive passenger comfort and convenience, battery thermal management, remote power generation, patient temperature management, and other consumer and industrial temperature control needs. Gentherm’s automotive products can be found on the vehicles of nearly all major automotive manufacturers operating in North America, Europe, and Asia. The company identifies future thermal technology product opportunities in both automotive and other markets. It concentrates research on the development of new technologies and new applications from existing technologies to create product and market opportunities for a wide array of thermal management solutions.

Company Headquarters: The Netherlands Founded:2006 Workforce: ~15,000 Company Working: Gemalto N.V. (Gemalto) is a provider of digital security products and services, including microprocessor cards and secure personal devices. The company develops and installs software in diverse products, including subscriber identity module (SIM), payment cards, and electronic identification (eID) documents, and others. It also offers platforms and services to monitor and manage these devices, check identities, and manage transactions. Gemalto was acquired by Thales Group in April 2019. Moreover, Gemalto operates through two reportable business segments, namely identity, IoT & cybersecurity, and smartcards & issuance. The company offers e-SIMs through both these segments that combine businesses associated with mobile cellular technologies, mobile network operators, and industrial organizations. For mobile network operators, the company's solutions include SIM/universal integrated circuit card (UICC) cards and back-office platforms and services, including roaming optimization, mobile payment, mobile marketing, personal data management, and trusted service management (TSM). For industrial organizations, Gemalto offers solutions designed to address the needs of a range of market verticals such as utilities, health, and automotive. These industrial solutions enable machine-to-machine (M2M) data exchange through hardware modules and operating software that connect machines to digital networks. It also offers cloud-based M2M application enablement and late-stage personalization (LSP) platforms. The company operates in Europe, North and South America, the Middle East and Africa, and Asia-Pacific.

Normal 0 false false false EN-US X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin-top:0in; mso-para-margin-right:0in; mso-para-margin-bottom:8.0pt; mso-para-margin-left:0in; line-height:107%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Roboto Condensed"; mso-ascii-font-family:"Roboto Condensed"; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:"Roboto Condensed"; mso-hansi-theme-font:minor-latin;} Company Headquarters: Malaysia Founded: 1997 Workforce: ~2,368 Company Working: Scicom (MSC) Bhd (Scicom) is a Malaysian technology and business process outsourcing (BPO) company. The company also offers end-to-end services, deploys integrated and advanced solutions to the clients to digitally transform their businesses. It offers outsourced solutions to multi-national and international corporate clients, domestic conglomerates, larger SMBs, and governments. It has been a public listed company (PLC) since 2005 on the main board of Bursa Malaysia. The company operates from four centers in Kuala Lumpur and Colombo; it has also opened new e-solutions centers. The e-solution centers are served by IT Infrastructure in the Scicom Private Cloud and linked via OCEAN, the company’s network. The services include integrated BPO and contact centers, education, e-commerce, e-government, and digital marketing solutions. Scicom has developed identity management solutions for the homeland and border security markets and digital government solutions for government clients. For identity management solutions, the company has developed the following solutions – e-visa processing, border control systems, advance passenger screening platforms, biometric platforms, citizen identification solutions, digital identity solutions (electronic know your customer), international student management systems, and migrant worker management systems.The majority of the solutions focus on digital government services and solutions for federal, local and state government clients. The company offers e-government solutions which are customized according to the client’s specific needs.

Company Headquarters: India Founded: 1983 Workforce: ~25,000 Company Working: BLS International is a global provider of visa, passport, consular, and citizen services to governments and diplomatic missions. The company is headquartered in New Delhi, India and has a presence in over 66 countries with more than 25,000 employees serving clients in various sectors. The company has 15,500 Centers across the globe. BLS International offers a wide range of services, including visa processing, passport services, document attestation, consular services, and eVisa services. The company partners with several governments and diplomatic missions worldwide to provide these services, including the Government of India, the Embassy of the United Arab Emirates in New Delhi, the High Commission of Canada in India, and the Royal Thai Embassy in New Delhi. In addition, BLS International also provides outsourcing services to governments, such as biometric enrollment, identity management, and document management. The company leverages technology and innovation to streamline its services and provide customers with a seamless and efficient experience. With over three decades of experience in the industry, BLS International has established itself as a leading provider of visa and passport services globally, with a commitment to customer satisfaction and operational excellence.

Company Headquarters: Massachusetts, US Founded: 1956 Workforce: ~488 Company Working: Lantheus Medical Imaging, Inc. (Lantheus) is a global leader in the manufacturing, developing, and commercializing of innovative diagnostic medical imaging products. The company provides diagnostic imaging and nuclear medicine products primarily used for the diagnosis of cardiovascular diseases. Clinicians use these imaging agents and products across a range of imaging modalities, including echocardiography and nuclear imaging. Its commercial products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, technologists, and sonographers working in a variety of clinical settings. The company sells its products to radio pharmacies, integrated delivery networks, hospitals, clinics, and group practices.

Normal 0 false false false EN-US X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin-top:0in; mso-para-margin-right:0in; mso-para-margin-bottom:8.0pt; mso-para-margin-left:0in; line-height:107%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Roboto Condensed"; mso-ascii-font-family:"Roboto Condensed"; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:"Roboto Condensed"; mso-hansi-theme-font:minor-latin;} Company Headquarters: GERMANY Founded: 1981 Workforce: ~3,300 Company Working: Muehlbauer AG is a manufacturer of technological products and systems. It also offers software solutions for various applications such as production and personalization of cards, passports, and radio frequency identification. It offers plastic and smart cards, passports/e-passports, forming systems, precision parts, and other related products. Other business offerings are the sorting of microchips, carrier tape systems as well as automation, and labeling and traceability systems. The company operates through three divisions– Parts and Systems, Automation and Tecurity. The Parts & Systems division of the company manufactures high-precision components for safety-sensitive sectors such as aerospace or medical technology. Under its Automation division, the company develops, produces, and sells machines and automation solutions for the semiconductor backend, RFID/smart label, ID solutions, and solar sectors. In the Tecurity business unit, the company acts as a system partner and offers comprehensive solutions in the field of Smart ID from the initial conception to the final issue and verification of ID documents.

Company Headquarters: Shenyang, Liaoning China Founded: 1998 Workforce: 10,001 Company Working: Neusoft Corporation (Neusoft) deals in providing innovative information technology-enabled solutions and services to meet the unmet demands of its customers. Neusoft was established at Northeastern University, China. It has ten software research and development bases, eight regional headquarters, and a comprehensive marketing and service network covering over 60 cities across China, as well as subsidiaries in the US, Europe, Japan, the Middle East, and South America. It helps industry customers establish best practices in business development and management.

Company Headquarters: Haifa Bay, Israel Founded: 1959 Workforce: ~1,490 Company Working: Taro Pharmaceuticals Industries Ltd is a research-based, international, specialty pharmaceutical company that develops, manufactures, and markets prescription and over the counter (OTC) pharmaceutical products. The company offers its products primarily in the areas of topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, anti-inflammatory, and other therapeutic categories.

Normal 0 false false false EN-US X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin-top:0in; mso-para-margin-right:0in; mso-para-margin-bottom:8.0pt; mso-para-margin-left:0in; line-height:107%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Roboto Condensed"; mso-ascii-font-family:"Roboto Condensed"; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:"Roboto Condensed"; mso-hansi-theme-font:minor-latin;} Company Headquarters: Netherlands Founded: 1836 Workforce: ~18,553 Company Working: Wolters Kluwer is a leading provider of software and services for clinicians, nurses, accountants, lawyers, and has applications in finance, audit, risk, compliance, and regulatory fields. The solutions provided by the company help its customers to get better analytics and improve the overall productivity. It operates through four business segments, namely health, tax & accounting, governance, risk & compliance and legal & regulatory. The tax and accounting solutions are offered under the tax & accounting business segment. It provides tax and accounting solutions for businesses of all sizes across the globe.

Company Headquarters: London, UK Founded: 2015 Workforce: 4,500 employees Company Working: The company is engaged in developing and delivering advanced medical devices for healthcare systems. The company operates in two segments, namely, cardiac surgery and neuromodulation. The company offers VNS Therapy in the brain implants market. The company has a presence in more than 100 countries.

Company Headquarters: Massachusetts, US Founded: 1979 Workforce: ~36,000 Company Working: Boston Scientific Corporation is a worldwide developer, manufacturer, and marketer of medical devices used in a range of interventional medical specialties. The company collaborates with healthcare professionals to develop a broad portfolio of meaningful innovations that improve outcomes, reduce costs, and increase efficiencies. Its product portfolio is majorly divided into endoscopy, interventional cardiology, neuromodulation, peripheral interventions, rhythm management, and urology & pelvic health. In addition, Boston Scientific serves hospitals, clinics, outpatient facilities and medical offices across the world. Boston Scientific Corporation's manufacturing facilities are located across Malaysia, the US, and Ireland. Apart from this, it has a presence in countries like Japan, the Netherlands, France, Poland, India, China, Turkey, South Africa, and Singapore.

Alpek is the Americas' largest integrated polyester producer and one of the world's leading PET makers, with 7.6 million tonnes of installed capacity across 30 plants in nine countries. Its Polyester chain (PTA, PET resin, PET sheet, recycled PET) generated 71% of FY2025 sales; Plastics & Chemicals (Mexico's only polypropylene producer, the Americas' largest expandable polystyrene producer, specialty chemicals) generated 20% of sales but 43% of Comparable EBITDA; an emerging energy-commercialisation business supplied the balance. After three years of Chinese-driven oversupply, impairments and leverage that peaked at 4.4x, Alpek emerged from ALFA's control in 2025 as a fully independent, 100% free-float company. A 2026 margin and freight spike linked to Middle East conflict has lifted guidance to US$750–800 million of Comparable EBITDA and cut leverage to 2.2x. The investment question is whether that windfall is used to lock in a structurally stronger balance sheet before conditions normalise. --- **The company's own description.** The 2Q26 Earnings Report describes Alpek as a leading petrochemical company operating two segments: Polyester (PTA, PET resin and sheet, rPET) and Plastics & Chemicals (PP, EPS, and other specialty and industrial chemicals). It states that Alpek is a leading producer of PTA, PET resin and PET sheet worldwide, a leading rPET and EPS producer in the Americas, and the only producer of PP in Mexico. The 2025 financial statements add that it is the main integrated polyester producer in the Americas, operates the continent's largest EPS plant and one of North America's largest PP plants. **Independent characterisation.** Alpek is a spread business. It buys paraxylene, monoethylene glycol, propylene and styrene, converts them into commodity polymers and sells on formula-linked contracts ("cost-plus" in much of its North American polyester book) and at import-parity prices elsewhere. Earnings are therefore driven by four external variables that management itself uses in guidance: the Chinese/Asian integrated PET reference margin, the ocean freight rate from Asia to the Americas (which sets the import-parity cushion), North American PP and EPS reference margins, and the peso/dollar rate. Raw-material price moves create large non-cash inventory gains and losses, which is why the company reports "Comparable EBITDA" excluding them. **Revenue model.** Essentially 100% product sales, recognised at the point control of goods transfers (the sole key audit matter in the 2025 audit). There is no subscription or licensing revenue of note, although Alpek owns proprietary PTA and PET process technology. The "Others" line (9% of FY2025 sales) is mostly energy commercialisation: natural gas marketing in Mexico (more than 450 million cubic feet per day, 90% to third-party customers per the April 2026 presentation), now extending to power and to Brazil. **Value-chain position.** Midstream petrochemicals: downstream of refiners and crackers (paraxylene, MEG, propylene, styrene, pentane) and upstream of converters (bottle blowers, thermoformers, film and fibre makers, moulders). Conversion yields disclosed by the company: 0.66 t paraxylene per tonne PTA; 0.84 t PTA and 0.34 t MEG per tonne PET; 1.01 t propylene per tonne PP; 0.94 t styrene and 0.06 t pentane per tonne EPS. **Customers and end-markets.** By 2025 volume: food and beverage 69%, consumer goods 17%, housing and construction 14%; the company classifies 87% of volume as "resilient end-markets". By 2025 sales geography: USA/Canada 36%, Mexico 36%, South America 17%, Europe 6%, Middle East 3%, Asia and others 1%. Sales outside Mexico were 64% and 95% of sales are dollar-based (April 2026 presentation). Customers are brand owners and converters in beverages, food packaging, personal care, automotive, construction insulation and appliances; individual customer names and concentration are not publicly disclosed in the sources reviewed.

Company Headquarters: Pennsylvania, United States Founded: 2010 Workforce: ~ 3,400 Company Working: Trinseo is a leading global materials company that specializes in the production and distribution of innovative and sustainable solutions. With a rich heritage and a diverse product portfolio, Trinseo serves a wide range of industries, including automotive, consumer electronics, packaging, construction, and more. The company's product offerings encompass a variety of materials, including plastics, latex, synthetic rubber, and styrene-based products. Trinseo is committed to delivering value through innovation, quality, and sustainability. The company's dedicated team of researchers and engineers continuously develop new technologies and applications to meet the evolving needs of customers. The company has its presence in Europe, Asia Pacific, and United States. Trinseo places a strong emphasis on sustainability and actively integrates eco-friendly practices into its operations, striving to reduce environmental impact throughout the product lifecycle.

SABIC is one of the world's largest diversified petrochemical producers. It is the chemicals arm of Saudi Aramco, which holds its 70% controlling stake. SABIC converts advantaged Saudi feedstock (ethane, propane and naphtha) into commodity chemicals, polymers, specialty engineering resins and nitrogen fertilisers, and sells them to customers in more than 140 countries. The group is in the middle of its deepest structural reset in five decades. It has exited steel (Hadeed), shut uncompetitive European crackers, and sold its European petrochemicals and Americas/European engineering-thermoplastics businesses. That reset produced a record SAR 25.78bn net loss in FY2025, driven mainly by non-cash write-downs, while free cash flow rose 17% to SAR 7.2bn. The new strategy rests on four pillars: Gulf-cost-advantaged core assets, a re-separated high-margin Specialties segment, Asian growth (the Fujian complex starting up in Q4 2026 and the Rongsheng PDA), and a USD 3bn-by-2030 transformation program. A conservative balance sheet underpins all of this. In 2026 the company was simultaneously stress-tested by Strait of Hormuz shipping disruption. --- ### Company self-description (paraphrased from latest filings) In its FY2025 and Q2 2026 earnings releases, SABIC describes itself as one of the world's largest petrochemical manufacturers. It is a public company based in Riyadh, 70% owned by Aramco (via Aramco Downstream Company), with the remaining 30% traded on the Saudi Exchange. It serves customers in more than 140 countries. The Q2 2026 release frames the operating priorities as operational excellence, portfolio optimisation, corporate transformation and selective growth. ### What the company does SABIC is a vertically integrated, feedstock-advantaged chemicals producer organised into three reporting segments from FY2026 onward: 1. **Petrochemicals** (Chemicals plus Polymers), the core of the group. - Chemicals: olefins (ethylene, propylene), glycols (MEG), methanol, MTBE, aromatics and intermediates. - Polymers: polyethylene (HDPE, LLDPE, LDPE), polypropylene and polycarbonate. - The segment generated SAR 42.23bn of H1 2026 gross revenue, about 83% of the group total (Q2 2026 Earnings Release). 2. **Specialties.** Specialty resins, customised compounds and reactive additives. This was re-separated from the Polymers sub-segment in 2026. H1 2026 revenue was SAR 3.62bn (about 7%). 3. **Agri-Nutrients.** Urea, ammonia and other nitrogen fertilisers, held through the separately listed SABIC Agri-Nutrients Company (Tadawul: 2020). H1 2026 revenue was SAR 5.11bn (about 10%). ### Business and revenue model **Revenue mix:** Close to 100% product sales of physical goods, sold on spot and contract pricing linked to international benchmarks (Asian and European polyolefin, MEG, methanol and urea indices). There is no material subscription or licensing revenue. SABIC does license certain proprietary process technology and catalysts; for example, the 1 mtpa MTBE plant uses proprietary SABIC technology (Q2 2026 release). Licensing revenue is not separately disclosed. **Margin model:** A spread business: product price minus feedstock and energy cost. Saudi regulated ethane and gas pricing gives a structural cost advantage over naphtha-based European and Asian producers. **Value chain position:** Upstream to midstream. SABIC sits between Aramco (crude, gas and feedstock supply) and converters/OEMs (packaging, automotive, construction, electronics, agriculture). Specialties and compounding move it closer to OEM specification and design-in. **Customer types:** - Plastic converters (film, moulding, pipe) - Fibre and PET producers (MEG) - Fuel blenders (MTBE) - Formaldehyde and MTO producers (methanol) - Automotive, electrical/electronics and healthcare OEMs (Specialties) - Fertiliser distributors and government tenders (urea) **End-markets:** Packaging; consumer goods; building and construction; automotive and transportation (including EV, via the CEER MoU of July 2026); electrical and electronics (including PCB laminates for AI data centres and 5G); healthcare; agriculture; and energy/fuels. ### Independent characterisation SABIC is a cyclical, cost-curve-advantaged commodity producer with a small and growing specialty wedge. Its earnings are highly geared to the global petrochemical cycle, which in 2023–2025 was in a deep downturn caused by Chinese capacity additions and weak demand. A sovereign-linked parent, a net-cash or low-net-debt balance sheet and a long dividend record partly offset that cyclicality. The 2023–2026 portfolio actions convert SABIC from a globally dispersed, partly high-cost asset base into a Gulf-centred export platform with selective Asian equity positions. The trade-off is greater concentration on Middle East logistics, a risk that materialised in 2026 when Hormuz disruption cut Q2 2026 sales volumes.

Company Headquarters: New Jersey, US Founded: 1891 Workforce: ~69,000 Company Working: Merck & Co., Inc. (Merck) is a leading global biopharmaceutical company that develops prescription medicines, vaccines, biologic therapies, and animal health products. The company operates in more than 140 countries to deliver innovative health solutions. It operates through pharmaceutical, animal health, and healthcare services segment. The pharmaceutical segment includes human health pharmaceutical and vaccine products. The animal health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment, and control of diseases in livestock and companion animal species, which it sells to veterinarians, distributors, and animal producers. The healthcare services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients.